Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: N.V. Organon, Kloosterstraat 6, NL-5349 AB Oss, The Netherlands
Sycrest 5 mg sublingual tablets.
| Pharmaceutical Form |
|---|
|
Sublingual tablet. Round, white to off-white, sublingual tablets debossed with “5” on one side. |
Each sublingual tablet contains 5 mg asenapine (as maleate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Asenapine |
The mechanism of action of asenapine is not fully understood. However, based on its receptor pharmacology, it is proposed that the efficacy of asenapine is mediated through a combination of antagonist activity at D2 and 5-HT2A receptors. Actions at other receptors e.g. 5-HT1A, 5-HT1B, 5-HT2C, 5-HT6, 5-HT7, D3, and a2-adrenergic receptors, may also contribute to the clinical effects of asenapine. |
| List of Excipients |
|---|
|
Gelatin |
Peelable aluminium/aluminium blisters in cartons of 20, 60 or 100 sublingual tablets per carton.
Not all pack sizes may be marketed.
N.V. Organon, Kloosterstraat 6, NL-5349 AB Oss, The Netherlands
EU/1/10/640/001
EU/1/10/640/002
EU/1/10/640/003
Date of first authorisation: 01 September 2010
Date of latest renewal: 05 May 2015
| Drug | Countries | |
|---|---|---|
| SYCREST | Austria, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Japan, Lithuania, Poland, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
